(+) Epicatechin to Treat Friedreich's Ataxia

Inclusion Criteria: * Confirmed diagnosis of Friedreich's Ataxia (FA) by Frataxin genetic testing and/or Frataxin enzyme analysis * Between age 10 and 50 years of age, inclusive * Body weight of 25 kilograms or higher * Minimum of one affected organ (cardiac or neurological) system, as evidenced by clinical signs/symptoms * Disease duration ≤7 years, based on onset date of FA symptoms * Has no known contraindication to gadolinium contrast such as severe allergy or Glomerular Filtration Rate \<30 ml/min/m\^2. * Has no known contraindication to non-contrast Magnetic Resonance Imaging (MRI) evaluation such as pacemaker or magnetically active metal fragments. * Women of childbearing age must: * Have a negative pregnancy human chorionic gonadotropin test prior to receiving study drug. * Agree to use contraception for the duration of the study drug dosing, plus 1 month after completion of the study. Exclusion Criteria: * Advanced cardiac failure, New York Heart Association (NYHA) Classification Scale-Class IV (advanced stage heart failure) * Clinically significant comorbidities that may also lead to cardiomyopathy, for example long standing hypertension, familial cardiomyopathy. * Clinically significant comorbidities that would, in the opinion of the investigators, compromise the interpretation of test results. * Pregnant, breast-feeding or planning to become pregnant during study timeframe. * Patients with contraindications to regadenoson, i. e. second- or third-degree atrioventricular (AV) block or sinus node dysfunction. Has received an investigational drug within thirty (30) days of baseline visit. * Thrombocytopenia (\<125 x 10\^9/Liter) or prolonged Prothrombin Time/Partial Thromboplastin Time (PT/PTT) at baseline. * Clinically significant hypotension (systolic blood pressure \<90) due to heart failure or other conditions.